Everyday Health on MSN
SGLT2 inhibitors and IgAN: Can this diabetes drug delay kidney decline?
Explore the potential of SGLT2 inhibitors for IgAN. Learn how these diabetes drugs slow kidney damage progression when added to standard treatment.
MADRID — Nearly half of people with type 2 diabetes (T2D) currently recommended to receive sodium-glucose cotransporter 2 (SGLT2) inhibitors for kidney protection would not actually benefit from them, ...
In a new study published in Kidney International, researchers report that drugs known as SGLT2 inhibitors prevented ...
Although both sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Nihar R. Desai, MD ...
SGLT2 inhibitors combat inflammation and slow kidney disease by elevating S-adenosylmethionine (SAM) levels, which suppress inflammatory gene activity through epigenetic modification. The benefits of ...
The SGLT2 inhibitor medicines have changed how heart failure is managed. Originally sodium-glucose cotransporter 2 (SGLT2) inhibitors were used to lower blood sugar levels in people who have type 2 ...
CHICAGO -- SGLT2 inhibitor use was linked to reduced progression of in-situ pulmonary adenocarcinoma, an observational study showed. Nodule growth over the median 28 months of follow-up was 62% less ...
Uptake of sodium-glucose cotransporter 2 (SGLT2) inhibitors among US patients eligible for treatment according to clinical guidelines is extremely low, no matter their diabetes status, according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results